Cancer: It's Personal | Home Page. Could Aspirin be a Viable Adjuvant Treatment for Cancer? - Cancer Network. Epidemiological evidence as well as evidence from recent randomized trials suggest that aspirin may be of use in the adjuvant setting to treat cancer. Dr. Ruth E Langley and colleagues provide an overview of the evidence in favor of aspirin in cancer despite aspirin being “neither new nor expensive,” in a recent review in the British Journal of Cancer.[1] Aspirin 3D model; source: Wikimedia Commons, user Rob Hooft Despite being under the radar as a potential antineoplastic agent, the authors highlight continuing in vitro, preclinical, and in-human trials that are helping to uncover the mechanisms of aspirin in eliciting a tumor response.
Recent randomized trials that have aimed to show that aspirin can help to prevent cardiovascular disease have also shown a reduction in cancer incidence with long-term patient follow-up. Aspirin inhibits the two isoforms of cyclooxygenase, COX-1 and COX-2, located in blood vessels, the stomach, and the kidneys. GE Healthymagination | Healthy Living | Health Articles | Wellness. Whole-Genome Study of ER+ Breast Tumors: Treatment Clues and Complexity - Cancer Network.
A team from the Washington University School of Medicine and the Siteman Cancer Center, St. Louis, has sequenced whole genomes of tumors from 50 women with luminal (ER and/or PR positive) HER2 negative breast cancer. The researchers compared the sequences to matched DNA from the same patients’ healthy cells, to identify mutations present only in the cancer cells. Because endocrine therapy–resistant HER2 negative breast cancer is clinically aggressive and is the most common cause of breast cancer–related death, the researchers also sought to identify specific mutations linked to treatment outcomes. The study represents one of the largest cancer genomics investigations reported, with more than 10 trillion chemical bases of DNA sequenced. While its results underscore the complexity of breast cancer biology, the mutations uncovered may provide further clues to inform personalized therapy of this common breast cancer subtype. Lead investigator Matthew J. In discussing the study, Dr.
United States - Breast Cancer | International Cancer Genome Consortium.